van Rooij Josephus L M, Tokarska Klaudia A, Ten Dam-van Loon Ninette H, Wessels Peter H, Seute Tatjana, Minnema Monique C, Snijders Tom J
Department of Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
Department of Ophthalmology, University Medical Center Utrecht, 3508 GA Utrecht, The Netherlands.
Cancers (Basel). 2022 Jun 16;14(12):2967. doi: 10.3390/cancers14122967.
Primary vitreoretinal lymphoma (PVRL) is either unilateral or bilateral at initial presentation. Progression to a central nervous system (CNS) lymphoma is regularly observed and these patients seem to have an inferior survival. Knowledge of the predictive value of laterality for CNS progression may facilitate risk stratification and the development of more effective treatment strategies, and eventually, improve outcomes. The objective of this analysis is to estimate the risk of CNS progression for patients with bilateral versus unilateral involvement of PVRL.
Systematic literature search for studies on CNS progression in PVRL with bilateral and unilateral involvement according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We assessed the risk of bias and the methodological quality of studies using the Quality in Prognosis Studies (QUIPS) tool. Risk ratios of CNS progression in PVRL with bilateral and unilateral involvement were calculated and combined via a meta-analysis.
Twenty-five small-sized (total = 371 cases) studies were included. The majority of the studies were at medium to high risk of bias. Results suggest no significant difference in CNS progression between bilateral and unilateral PVRL, with a pooled relative risk ratio of 1.12 (95% confidence interval 0.89-1.41).
CNS progression is common in PVRL. From the limited available evidence, there is no significant difference in CNS progression between bilateral and unilateral PVRL.
原发性玻璃体视网膜淋巴瘤(PVRL)初发时可为单侧或双侧。经常观察到其进展为中枢神经系统(CNS)淋巴瘤,且这些患者的生存率似乎较低。了解病变侧别对CNS进展的预测价值可能有助于风险分层和制定更有效的治疗策略,并最终改善预后。本分析的目的是评估PVRL双侧受累与单侧受累患者发生CNS进展的风险。
根据系统评价和Meta分析的首选报告项目(PRISMA)指南,系统检索关于PVRL双侧和单侧受累时CNS进展的研究。我们使用预后研究质量(QUIPS)工具评估研究的偏倚风险和方法学质量。计算并通过Meta分析合并PVRL双侧和单侧受累时CNS进展的风险比。
纳入了25项小型研究(共371例病例)。大多数研究存在中度至高偏倚风险。结果表明,双侧和单侧PVRL的CNS进展无显著差异,合并相对风险比为1.12(95%置信区间0.89 - 1.41)。
CNS进展在PVRL中很常见。根据有限的现有证据,双侧和单侧PVRL的CNS进展无显著差异。